KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Common Equity (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Common Equity for 16 consecutive years, with $371.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 6.59% to $371.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $371.9 million through Dec 2025, up 6.59% year-over-year, with the annual reading at $371.9 million for FY2025, 6.59% up from the prior year.
  • Common Equity for Q4 2025 was $371.9 million at Biolife Solutions, up from $353.7 million in the prior quarter.
  • The five-year high for Common Equity was $489.3 million in Q3 2021, with the low at $208.8 million in Q1 2021.
  • Average Common Equity over 5 years is $370.9 million, with a median of $353.2 million recorded in 2025.
  • The sharpest move saw Common Equity surged 327.31% in 2021, then dropped 24.78% in 2023.
  • Over 5 years, Common Equity stood at $478.0 million in 2021, then dropped by 23.82% to $364.2 million in 2022, then dropped by 7.28% to $337.7 million in 2023, then grew by 3.33% to $348.9 million in 2024, then increased by 6.59% to $371.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $371.9 million, $353.7 million, and $347.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.